Prenatal valproate exposure and adverse neurodevelopmental outcomes: Does sex matter?
Eliza Honybun, Rebecca Thwaites, Charles B Malpas, Genevieve Rayner, Alison Anderson, Janet Graham, Alison Hitchcock, Terence J O'Brien, Frank JE Vajda, Piero Perucca
Epilepsia | WILEY | Published : 2021
OBJECTIVE: Prenatal exposure to the antiepileptic drug (AED) valproic acid (VPA) is associated with an increased risk of impaired postnatal neurodevelopment, including autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD). We aimed to evaluate the influence of sex and drug dosage on the association between prenatal VPA exposure and postnatal behavioral outcomes. METHODS: The Australian Pregnancy Register of AEDs was interrogated to identify children aged 4-11 years prenatally exposed to AEDs. Parents reported on their child's behavior using the Autism Spectrum Quotient-Children's Version and the National Institute for Children's Health Quality Vanderbilt Assessme..View full abstract
Epilepsy Action Australia; Epilepsy Society of Australia; the Royal Melbourne Hospital Neuroscience Foundation; Sanofi-Aventis; Genzyme; UCB Pharma; Janssen-Cilag; Sci-Gen; Eisai